CollPlant, a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).
Headquartered in Manchester, New Hampshire, ARMI brings together a consortium of over 150 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.
Approximately $80 million from the US federal government is combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. ARMI leads the Advanced Tissue Biofabrication Manufacturing Institute on behalf of the US Department of Defense. ARMI works to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition. ARMI focuses on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs. ARMI's efforts are supported by industrial partners, academic and academically affiliated partners, and government and nonprofit partners. The ARMI partnership continues to grow.
ARMI's Chairman, inventor Dean Kamen stated, "We need to develop 21st century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a 15th century tool (the printing press) allowed knowledge to spread widely during the Renaissance. As an ever-growing ecosystem of industrial, governmental, academic, non-profit and clinical institutions, I have no doubt that we can achieve our mission to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies, to benefit existing industries and grow new ones."
Yehiel Tal, CollPlant's Chief Executive Officer commented, "CollPlant is very pleased to enter into this collaboration with ARMI and its network of partners from industry, academia, and the U.S. federal government. We all share the common goal of advancing 3D bioprinting and next-generation manufacturing of tissues and organs. We believe CollPlant's BioInks, based on our rhCollagen, are the ideal building block for tissue and organ manufacturing, and we are proud to contribute our expertise and to advance the entire science and industry of bioengineering and manufacturing. CollPlant is honored to be a part of this network of industry leaders."
For more information about CollPlant, visit http://www.collplant.com